Trastuzumab deruxtecan for unresectable or metastatic HER2-positive solid tumours after at least one prior line of systemic therapy

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable or metastatic human epidermal growth receptor 2 (HER2)-positive solid tumours who show progression after at least one prior systemic treatment and who have no satisfactory alternative treatment options. The decision was based on uncertainties in the positioning of T-DXd relative to current management, its clinical and cost effectiveness across different cancer types, and its uncertain budget impact.

Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.

Guidance_Trastuzumab deruxtecan for unresectable or metastatic HER2-positive solid tumours after at least one prior line of systemic therapy (6 Feb 2026)